A1chieve Program in Russian Federation: a multicenter prospective observational study of insulin analogue treatment efficiency and safety in daily management of patients with type 2 diabetes mellitus, who startand intensify insulin treatment having never received it before
Abstract
Prevalence rate of diabetes mellitus worldwide and in Russian Federation is epidemic in its nature. Prospective studies have shown thatmaintenance of glycemic target reduces risk of late vascular complications. In turn, strict glycemic control requires modern approach tointensification of glucose lowering therapy. Randomized clinical trials prove capacity of modern insulin analogues to improve glycemiccontrol while decreasing risk of hypoglycemic events and weight gain. Current paper presents initial data on 9342 patients, participatedin multicenter prospective 52-week observational study A1chieve, conducted in order to assess efficiency and safety of treatment withinsulin analogues Levemir?, NovoMix? and NovoRapid? (Novo Nordisk) in daily management of patients with type 2 diabetes mellitus,who never received that treatment before.
References
1. International Diabetes Federation Atlas 5th edition; 2011.
2. Алгоритмы специализированной медицинской помощи больным сахарным диабетом (5-й выпуск). Под ред. И.И. Дедова и М.В. Шестаковой. 2011. 116 С.
3. Сунцов ЮИ. Эпидемиология сахарного диабета и прогноз его распространенности в Российской Федерации. Сахарный диабет. 2011;(1):15-19.
4. UK Prospective Diabetes Study (UKPDS) Group. UKPDS Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet. 1998 Sep 12;352(9131):837-853.
5. Nathan DM, Buse JB, Davidson MB, Ferrannini E, Holman RR, Sherwin R, Zinman B; American Diabetes Association; European Association for the Study of Diabetes. Medical management of hyperglycaemia in type 2 diabetes mellitus: a consensus algorithm for the initiation and adjustment of therapy. A consensus statement from the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care. 2009 Jan; 32 (1): 193-203.
6. American Diabetes Association. Standarts of medical care in Diabetes - 2011. Diabetes Care. 2011; 34 (1): 11-61.
7. Дедов ИИ, Шестакова МВ, Аметов АС, Анциферов МБ, Галстян ГР, Майоров АЮ, Мкртумян АМ, Петунина НА, Сухарева ОЮ. Консенсус совета экспертов Российской ас- социации эндокринологов по инициации и интенсификации сахароснижающей терапии сахарного диабета 2 типа. Са- харный диабет. 2011; (4): 6-18.
8. International Diabetes Federation. Global Guideline for Type 2 diabetes; 2005.
9. Riedel AA, Heien H, Wogen J, Plauschinat CA. Loss of glycemic control in patients with type 2 diabetes mellitus who were receiving initial metformin, sulfonylurea, or thiazolidinedione monotherapy. Pharmacotherapy. 2007 Aug;27(8):1102-1110.
10. Shah BR, Hux JE, Laupacis A, Zinman B, van Walraven C. Clinical inertia in response to inadequate glycemic control: do specialists differ from primary care physicians? Diabetes Care. 2005 Mar;28(3):600-606.
Review
For citations:
Shestakova M.V. A1chieve Program in Russian Federation: a multicenter prospective observational study of insulin analogue treatment efficiency and safety in daily management of patients with type 2 diabetes mellitus, who startand intensify insulin treatment having never received it before. Diabetes mellitus. 2012;15(1):63-70. (In Russ.)
Views:
633
Email this article 
